Last week, the US Food and Drug Administration (FDA) refused a tobacco application from an electronic cigarette company prior to their market release. The reason for the rejection was due to the potential risks associated with selling mint flavored products to young smokers.
The FDA has rejected a line of products from Logic Technology Development, stating that the company failed to demonstrate that their menthol-based products are more likely to help adult smokers quit than their flavorless options. Additionally, there are concerns that these products may encourage underage users to try them, leading to the FDA's decision to reject them.
Brian King, the director of the FDA Center for Tobacco Products (CTP), stated, "In this case, the applicant did not provide sufficient scientific evidence to demonstrate that the potential benefits for adult smokers outweigh the risks to youth.
The US Food and Drug Administration (FDA) is under pressure to revoke and ban products containing menthol.
Meanwhile, due to relentless criticism of CTP's handling of the ongoing PMTA process, earlier this year, FDA director Robert Califf announced that he would commission external experts to conduct a "comprehensive evaluation" of the center.
Last July, the organization was strongly criticized by Senator Dick Durbin (Democrat from Illinois) and Susan Collins (Republican from Maine). In a letter, the senators cited a report from STAT that stated the agency was lacking action in regards to the ban of synthetic nicotine announced earlier this year. The letter stated that the FDA "appears to be once again on the verge of failing in its responsibility to protect our nation's children.
Similarly, Matt Myers, the president of the Smoke-Free Kids campaign, emphasized the need for the US Food and Drug Administration to exercise its authority and remove these products from the market. "All unauthorized synthetic nicotine products are now illegal and must be removed from the market under the law, rather than at some uncertain date in the future," he said.
Furthermore, the agency has continually been criticized for failing to meet the required deadline and completing the PMTA process on time. Adding to this, the FDA has been forced to temporarily suspend its recently released Juul market denial order (MDO), stating that a more thorough review is necessary.
FDA's Tobacco Product Center under review.
In order to demonstrate that these errors are being taken seriously, a commissioner in California announced a review by the CTP. In a press release, he stated, "I have discussed this assessment with the leaders of these centers and offices, and they welcome the opportunity to strive for organizational excellence.
In every field, there are hardworking and talented individuals who devote their careers to various scientific, policy, legal, and administrative activities. FDA employees should receive the best possible support so that they can fulfill their commitment to public health and serve the American public with unwavering dedication.
Statement:
This article has been compiled from third-party information and is intended for industry communication and learning purposes.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The translation of this article is intended for industry communication and research purposes only.
Due to limitations in translation skills, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.
2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related expressions and positions.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
